Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bemnifosbuvir + ruzasvir + ethinyl estradiol + levonorgestrel
- Development stage
- Unknown
- Lead developer
- Atea Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
This drug combination is a regimen used in a Phase 1 clinical trial to evaluate drug-drug interactions between Atea Pharmaceuticals' investigational hepatitis C virus (HCV) treatment and a common oral contraceptive. The regimen consists of bemnifosbuvir (a nucleotide analog NS5B polymerase inhibitor), ruzasvir (an NS5A inhibitor), ethinyl estradiol (a synthetic estrogen), and levonorgestrel (a synthetic progestin). Bemnifosbuvir and ruzasvir are being developed as a pan-genotypic, once-daily oral treatment for chronic HCV infection, while ethinyl estradiol and levonorgestrel are standard components of birth control. The study aims to determine if the HCV antivirals alter the pharmacokinetics of the contraceptive hormones, which is critical for ensuring contraceptive efficacy and safety during antiviral therapy.
- Other names
- bemnifosbuvir/ruzasvir + ethinyl estradiol/levonorgestrel
02
Targets
NS5B (Hepatitis C virus non-structural protein 5B (NS5B) RNA-dependent RNA polymerase)ER (Estrogen receptor)PR (Progesterone receptor)NS5A (Hepatitis C virus nonstructural protein 5A (genotype 1b))
Beyond the preview
Go deeper on bemnifosbuvir + ruzasvir + ethinyl estradiol + levonorgestrel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bemnifosbuvir + ruzasvir + ethinyl estradiol + levonorgestrel.